i-SENS, Inc.

KOSDAQ 099190.KQ

i-SENS, Inc. Gross Profit for the year ending December 31, 2023: USD 81.45 M

i-SENS, Inc. Gross Profit is USD 81.45 M for the year ending December 31, 2023, a 1.77% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

i-SENS, Inc. Gross Profit for the year ending December 31, 2022 was USD 80.03 M, a -3.50% change year over year.
i-SENS, Inc. Gross Profit for the year ending December 31, 2021 was USD 82.94 M, a -1.67% change year over year.
i-SENS, Inc. Gross Profit for the year ending December 31, 2020 was USD 84.34 M, a 18.43% change year over year.
i-SENS, Inc. Gross Profit for the year ending December 31, 2019 was USD 71.22 M, a 5.55% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KOSDAQ: 099190.KQ

i-SENS, Inc.

CEO	Dr. Geun-Sig Cha
IPO Date	Jan. 30, 2013
Location	South Korea
Headquarters	43, Banpo-daero 28-gil
Employees	687
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years